Medicines for Cancer
Mechanism of Action and Clinical Pharmacology of Chemo, Hormonal, Targeted, and Immunotherapies
- 1st Edition - April 20, 2023
- Imprint: Elsevier
- Author: Surya K. De
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 1 3 3 1 2 - 1
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 3 3 1 3 - 8
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 8 5 2 1 - 9
Medicines for Cancer: Mechanism of Action and Clinical Pharmacology of Chemo, Hormonal, Targeted, and Immunotherapies covers most known anti-cancer therapeutics. Cancer is the se… Read more
Purchase options
Medicines for Cancer: Mechanism of Action and Clinical Pharmacology of Chemo, Hormonal, Targeted, and Immunotherapies covers most known anti-cancer therapeutics. Cancer is the second leading cause of death worldwide, with its various forms resulting in nearly one out of every six mortalities each year. This book describes all US FDA-approved drugs (up to 2021), such as small molecules, peptides, monoclonal antibodies, whole antibodies, gene therapy, antibody-drug conjugates, cell therapy, and immunotherapies, along with information on their generic and brand names, medical uses, details dosage, mechanisms of actions, pharmacokinetics and side effects. Chemical structures of small molecules, small peptides, antibody-drug conjugates are also provided.
This book is ideal for medicinal chemists, oncologists, and pharmacologists, but it will also be indispensable for professional researchers, whether they are working in the clinic or the pharmaceutical industry.
- Covers precise information on each drug treatment
- Catalogues and lists all FDA-approved drugs for cancer group by chemical classes
- Provides easy access to specific drugs
Researchers and postgraduate students in Medicinal Chemistry, Pharmacology, and other cancer-related fields. Oncologists and medical research professionals
Chapter 1: Nomenclature of drugs
Chapter 2: Chemotherapy Introduction 2.1.1 Alkylating antineoplastic agent 2.1.2 Nitrosoureas 2.2 Antimetabolites 2.3 Antitumor antibiotics 2.3.1 Anthracyclines 2.3.2 Non- Anthracyclines 2.4 Topoisomerase inhibitors 2.5 Mitotic inhibitors (Anti-microtubule Agents) 2.6 Corticosteroids 2.7 Other chemotherapy drugs 2.8 US FDA approved chemotherapy agents 2.9 Albumin-Bound Paclitaxel 2.10 Amifostine 2.11 Arsenic trioxide 2.12 Asparaginase Erwinia chrysanthemi 2.13 Azacitidine 2.14 Bendamustine 2.15 Bleomycin 2.16 Busulfan 2.17 Cabazitaxel 2.18 Calaspargase Pegol-mknl 2.19 Capecitabine 2.20 Carboplatin 2.21 Carmustine 2.22 Chlorambucil 2.23 Cisplatin 2.24 Cladribine 2.25 Clofarabine 2.26 Cyclophosphamide 2.27 Cytarabine 2.28 Dacarbazine 2.29 Dactinomycin 2.30 Daunorubicin 2.31 Decitabine 2.32 Dexamethasone 2.33 Docetaxel 2.34 Doxorubicin 2.35 Doxorubicin Liposome 2.36 Epirubicin 2.37 Eribulin Mesylate 2.38 Etoposide 2.39 Fludarabine 2.40 5-Fluorouracil 2.41 Gemcitabine 2.42 Hydroxyurea 2.43 Idarubicin 2.44 Ifosfamide 2.45 Irinotecan 2.46 Ixabepilone 2.47 Lomustine 2.48 Lurbinectedin 2.49 Lutetium Lu 177-Dotatate 2.50 Mechlorethamine 2.51 Melphalan 2.52 Mercaptopurine 2.53 Methotrexate 2.54 Mitomycin-C 2.55 Mitoxantrone 2.56 Nelarabine 2.57 Oxaliplatin 2.58 Paclitaxel 2.59 Pemetrexed 2.60 Pralatrexate 2.61 Procarbazine 2.62 Radium 223 Dichloride 2.63 Temozolomide 2.64 Thioguanine 2.65 Thiotepa 2.66 Topotecan 2.67 Trabectedin 2.68 Valrubicin 2.69 Vinblastine 2.70 Vincristine 2.71 Vinorelbine References
Chapter 3: Hormonal Therapy Introduction 3.1 Abiraterone acetate 3.2 Anastrozole 3.3 Apalutamide 3.4 Bicalutamide 3.5 Darolutamide 3.6 Degarelix 3.7 Enzalutamide 3.8 Exemestane 3.9 Flutamide 3.10 Fulvestrant 3.11 Goserelin 3.12 Lanreotide 3.13 Letrozole 3.14 Leuprolide (Leuprorelin) 3.15 Megestrol acetate 3.16 Nilutamide 3.17 Raloxifene 3.18 Relugolix 3.19 Tamoxifen 3.20 Toremifene References
Chapter 4: Targeted Therapy: Small Molecules Introduction 4.1 Abemaciclib 4.2 Acalabrutinib 4.3 Afatinib 4.4 Alectinib 4.5 Alpelisib 4.6 Avapritinib 4.7 Axitinib 4.8 Belinostat 4.9 Bexarotene 4.10 Binimetinib 4.11 Bortezomib 4.12 Bosutinib 4.13 Brigatinib 4.14 Cabozantinib 4.15 Capmatinib 4.16 Carfilzomib 4.17 Ceritinib 4.18 Cobimetinib 4.19 Copanlisib 4.20 Crizotinib 4.21 Dabrafenib 4.22 Dacomitinib 4.23 Dasatinib 4.24 Duvelisib 4.25 Enasidenib 4.26 Encorafenib 4.27 Entrectinib 4.28 Erdafitinib 4.29 Erlotinib 4.30 Everolimus 4.31 Fedratinib 4.32 Fostamatinib 4.33 Gefitinib 4.34 Gilteritinib 4.35 Glasdegib 4.36 Ibrutinib 4.37 Idelalisib 4.38 Imatinib 4.39 Imiquimod 4.40 Infigratinib 4.41 Iobenguane I 131 4.42 Ivosidenib 4.43 Ixazomib 4.44 Lapatinib 4.45 Larotrectinib 4.46 Lenalidomide 4.47 Lenvatinib 4.48 Lorlatinib 4.49 Midostaurin 4.50 Mobocertinib 4.51 Neratinib 4.52 Nilotinib 4.53 Niraparib 4.54 Olaparib 4.55 Omacetaxine Mepesuccinate 4.56 Osimertinib 4.57 Palbociclib 4.58 Pazopanib 4.59 Pemigatinib 4.60 Pexidartinib 4.61 Pomalidomide 4.62 Ponatinib 4.63 Pralsetinib 4.64 Regorafenib 4.65 Ribociclib 4.66 Ripretinib 4.67 Romidepsin 4.68 Rucaparib 4.69 Selinexor 4.70 Selpercatinib 4.71 Selumetinib 4.72 Sonidegib 4.73 Sorafenib 4.74 Sunitinib 4.75 Talazoparib 4.76 Tazemetostat 4.77 Temsirolimus 4.78 Tepotinib 4.79 Thalidomide 4.80 Tivozanib 4.81 Trametinib 4.82 Tucatinib 4.83 Umbralisib 4.84 Vandetanib 4.85 Vemurafenib 4.86 Venetoclax 4.87 Vismodegib 4.88 Vorinostat 4.89 Zanubrutinib 4.90 Zoledronic Acid References
Chapter 5: Targeted therapy: Monoclonal antibody Introduction 5.1 Alemtuzumab 5.2 Bevacizumab 5.3 Cetuximab 5.4 Daratumumab 5.5 Ibritumomab Tiuxetan 5.6 Isatuximab-irfc 5.7 Margetuximab-cmkb 5.8 Naxitamab-gqgk 5.9 Necitumumab 5.10 Obinutuzumab 5.11 Ofatumumab 5.12 Panitumumab 5.13 Pertuzumab 5.14 Ramucirumab 5.15 Rituximab 5.16 Tafasitamab 5.17 Tagraxofusp 5.18 Trastuzumab References
Chapter 6: Targeted Therapy: Antibody-drug conjugate (ADC) Introduction 6.1 Ado-Trastuzumab Emtansine 6.2 Belantamab mafodotin-blmf 6.3 Brentuximab vedotin 6.4 Enfortumab Vedotin-ejfv 6.5 Fam-Trastuzumab Deruxtecan-nxki 6.6 Gemtuzumab Ozogamicin 6.7 Inotuzumab Ozogamicin 6.8 Loncastuximab tesirine- lpyl 6.9 Polatuzumab Vedotin-piiq 6.10 Sacituzumab Govitecan-hziy 6.11 Tisotumab Vedotin-tftv
Chapter 7: Immunotherapy Introduction 7.1 Types of immunotherapies 7.1.1 Checkpoint inhibitors 7.1.2 T-cell transfer therapy/ Chimeric antigen receptor (CAR) T-cell therapy 7.1.3 Monoclonal antibodies 7.1.4 Immune system modulators 7.1.5 Treatment vaccines 7.2 Aldesleukin 7.3 Avelumab 7.4 Axicabtagene Ciloleucel 7.5 Blinatumomab 7.6 Brexucabtagene Autoleucel 7.7 Cemiplimab-rwlc 7.8 Denileukin Diftitox 7.9 Dinutuximab 7.10 Dostarlimab-gxly 7.11 Durvalumab 7.12 Elotuzumab 7.13 Idecabtagene Vicleucel 7.14 Ipilimumab 7.15 Lisocabtagene Maraleucel 7.16 Moxetumomab pasudotox- tdfk 7.17 Nivolumab 7.18 Pembrolizumab 7.19 Sipuleucel-T 7.20 Talimogene Laherparepvec 7.21 Tisagenlecleucel References
Appendix Table 1: A-Z list of cancer medicines (antineoplastics) Table 2: Small molecules targeted drugs for cancer Table 3: Monoclonal antibody as a targeted therapy Table 4: Antibody-drug conjugate as a targeted therapy Table 5: Immunotherapy agent
- Edition: 1
- Published: April 20, 2023
- Imprint: Elsevier
- Language: English
SD
Surya K. De
Dr De holds fifteen United States and international patents. Due to his abundant research contributions in the areas of cancer, metabolic diseases, organic and medicinal chemistry, and neuroscience, he has earned the distinction of Fellow of the Royal Society of Chemistry in 2010, and was subsequently awarded the status of Chartered Chemist in 2011. He is an elected Councilor in the American Chemical Society (San Diego section). He is editorial board member of Anticancer Agents in Medicinal Chemistry and Current Organic Synthesis.
Affiliations and expertise
American Chemical Society, San Diego, USARead Medicines for Cancer on ScienceDirect